Provided by Tiger Trade Technology Pte. Ltd.

Sequoia Capital Holdings

3,456.56
+14.570.42%
Number of Gainers:74
Number of Losers:25
Number of Flat:1
PE:- -
High:3,466.60
Open:3,441.78
Low:3,441.34
Close:3,441.99
Volume:1.01B
Turnover:209.05B
Market Cap:45.42T
Float Cap:42.45T

Loading ...

Yuyu Pharma Brings Ari's Purrfect to Amazon Accelerate 2026

THOMSON REUTERS
·
Sep 30

Coreweave to Offer Nvidia Vera, the First CPU Built for AI Agents

THOMSON REUTERS
·
Sep 30

Lenovo AI Express with Nvidia Accelerates Path to Hybrid AI Factory in Weeks

THOMSON REUTERS
·
Sep 30

Coreweave Delivers Nvidia Vera Rubin Nvl72 Performance at Production Scale, Starting with Cognition

THOMSON REUTERS
·
Sep 30

CScale Raises $145 Million for AI Networking, with Backing from Nvidia and Intel

Reuters
·
Sep 30

What the History of Electric Wires Can Teach Us About the Data Center Backlash

InvestorPlace
·
Sep 30

Breaking: Jensen Huang Set to Take On Role at Tsinghua University

Deep News
·
Sep 30

Silo Pharma Unit QwikAgents Adds Nvidia Nemotron Model Support

Reuters
·
Sep 30

Silo Pharma’s Qwikagents Expands AI Agent Platform with Nvidia Model Support and New Runtime Flexibility

THOMSON REUTERS
·
Sep 30

Grayscale Zcash Trust completes 3-for-1 share split

TIPRANKS
·
Sep 30

UBS Sticks to Its Hold Rating for Apple (AAPL)

TIPRANKS
·
Sep 30

Tesla's Cash Crunch Has Arrived-Blame Its AI Ambitions

Dow Jones
·
Sep 30

Labcorp to Report Third-Quarter 2026 Results, Host Webcast

Reuters
·
Sep 30

Harmonic Launches Recon Network Monitoring Product Family Developed With Comcast

MT Newswires Live
·
Sep 30

Labcorp to Announce Third Quarter 2026 Financial Results on October 28, 2026

THOMSON REUTERS
·
Sep 30

Merck Says Experimental Skin Disease Drug Meets Main Goal in Mid-Stage Study

Reuters
·
Sep 30

Honeywell Declares Q4 2026 Dividend of R$ 2.4172447320 Per Unit, Payable Dec. 15

Reuters
·
Sep 30

Merck Says Tulisokibart Hits Primary Endpoint in Phase 2b Hidradenitis Suppurativa Trial

Reuters
·
Sep 30

Merck & Co - Study Meets Primary Endpoint Hiscr50 at Week 16 for High- and Medium-Dose Tulisokibart

THOMSON REUTERS
·
Sep 30

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2B Study in Patients with Moderate to Severe Hidradenitis Suppurativa (Hs)

THOMSON REUTERS
·
Sep 30